Skip to main content
PRIMR23 SBER23 Main banner
Icon Legend
Presentation Icons
Pre-Reg Required
Pre-Reg Required
Additional Fee
Additional Fee
Livestreaming Session Icon
Livestreaming Session Icon
Live Session Recorded
Live Session Recorded
On-Demand Session
On-Demand Session
CIP Accredited
CIP Accredited
CPIA Accredited
CPIA Accredited
Call for Session Proposal
Call for Session Proposal
Human Subjects Research
Human Subjects Research
IACUC/Animal Care and Use
IACUC/Animal Care and Use
Crossover
Crossover
Institutional Leadership
Institutional Leadership
Workshop Series
Workshop Series
Thought Leader Series
Thought Leader Series
Deep Dive Series
Deep Dive Series
Learning Lab Series
Learning Lab Series
Networking Series
Networking Series
Vendor Insight Series
Vendor Insight Series
Pillars of PRIM&R Poster Award
Pillars of PRIM&R Poster Award
Poster Icons
Record Session Icon
Record Session Icon
Pre-Reg Required
Pre-Reg Required
Part I/II
Part I/II
CSP Icon
CSP Icon
Livestreaming Session Icon
Livestreaming Session Icon
Prerecorded Session Icon
Prerecorded Session Icon
CIP Accredited
CIP Accredited
Pillars Icon
Pillars Icon
Back

2023 PRIM&R Annual Conference

Animal Well-Being and the 3Rs

A Dialogue With the Feds

A20 - [ON-DEMAND] FDA and Alternatives

Monday, December 4, 2023
1:00 PM – 2:00 PM ET
On-Demand Session IACUC/Animal Care and Use Deep Dive Series
This session will be offered on-demand only for in-person PRIMR23 attendees registered for this day, and PRIMR23/SBER23 Virtual Meeting registrants; there is no live interaction.

The FDA sponsors and supports a range of alternative development programs. Attendees will learn about recent achievements, current programs underway, and what is coming next for the FDA in development of validated alternatives.

Learning Objectives:

  • Hear about the alternatives FDA is excited about in nonhuman animal research
  • Learn how FDA evaluates non-animal models and decide if it is an acceptable alternative in leu of nonhuman animal studies
  • Explore the process for applying for a new alternative to be considered for FDA acceptance